- This event has passed.
Fostering Patient-Clinician Communication: Trastuzumab Biosimilars
October 20, 2021 @ 11:00 am - 12:30 pm CDT
Title: Fostering Patient-Clinician Communication: Trastuzumab Biosimilars
Description: Some patients with HER2-positive breast cancer may switch from the biologic Herceptin to trastuzumab biosimilars. To learn about this topic, please join us for a presentation by topic expert Dr. Gary Lyman (Fred Hutchinson Cancer Research Center), followed by a discussion facilitated by Dr. Maryam Lustberg (Yale Cancer Center) with a multi-disciplinary panel comprised of a patient advocate (Ms. Sheila McGlown), oncology pharmacist (Dr. R. Donald Harvey, Emory Winship Cancer Institute), and infusion nurse (Leeann Valero, University of Illinois Hospital).
Learning Objectives:
- Improve your understanding of trastuzumab biosimilars, including efficacy and safety
- Gain an awareness of existing knowledge gaps from multiple perspectives
- Appreciate the value of lived experiences of patient-clinician communication regarding cancer treatment changes
Audience:
- Clinicians who treat & interact with HER2-positive breast cancer patients
- Patients and their caregivers
Featured Speaker:
Dr. Gary Lyman is a medical oncologist, hematologist, and public health researcher who focuses on comparative effectiveness, health technology assessment, and health services and outcomes research. Dr. Lyman serves as a senior leader for health care quality and policy within the Hutchinson Institute for Cancer Outcomes Research, or HICOR. An internationally recognized thought leader in cancer care delivery, supportive care, and health care policy, his research compares the effectiveness of novel diagnostic and therapeutic strategies; examines clinical decision-making; explores risk modeling and precision medicine; assesses health technology research and synthesis, and delves into the factors that drive disparities in cancer care. He is also interested in cancer prevention, pharmaco-economics, and cancer treatment, and supportive care for the elderly. Dr. Lyman is among the top 1% of investigators by citations in Web of Science. In addition to his work at the Hutch, Dr. Lyman holds leadership positions within the American Society of Clinical Oncology as well as the SWOG Cancer Research Network, for which he serves as executive officer for Cancer Care Delivery, Symptom Control, and Quality of Life Research.
Facilitator:
Dr. Maryam Lustberg, MD, MPH
Dr. Maryam Lustberg is Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She is also an Associate Professor of Medicine (Medical Oncology). She has been recognized for her patient-focused care with awards that include being rated by Forbes as one of the top breast medical oncologists in the nation and named to the Castle Connolly list of “Regional Top Doctors,” and “Exceptional Women in Medicine” for 2020. She is currently participating in the American Society of Clinical Oncology (ASCO) Leadership Development Program. With an emphasis on improving the long-term outcomes for patients with breast cancer who have developed side effects associated with treatment, Dr. Lustberg will continue her research efforts at Yale. She is also focused on investigating novel blood-based biomarkers to identify recurrence and treatment toxicity earlier. She is an NCI-funded investigator and active in both ALLIANCE and SWOG Cancer Cooperative Groups. Dr. Lustberg collaborates widely with researchers from around the world, thriving in creating innovative multidisciplinary scientific teams. Her mentorship has been recognized by numerous awards including Best Teacher Award by Hematology Oncology Fellows and the Shining Star Award for Medical Student Mentorship. Nationally, Dr. Lustberg is a member of the ASCO Annual Meeting Education Committee, Patient and Survivor Care Education Committee, and Neuropathy Expert Guideline Panel. She is actively engaged in national patient advocacy organizations with a focus on improving shared decision making and increasing patient engagement in clinical trials. In addition, she serves as the President Elect and on the Board of Directors for the international organization Multinational Association of Supportive Care in Cancer (MASCC). She serves as an Associate Editor for the Journal of Cancer Survivorship. In the last decade, she has published over 140 peer-reviewed publications and book chapters. Dr. Lustberg received her medical degree from the University of Maryland where she also completed her residency and went on to complete a fellowship in medical oncology and in breast medical oncology at The Ohio State University before joining the faculty in 2010. She earned a Master’s in Public Health from The Ohio State University in 2013.
Multi-Disciplinary Panel:
Sheila McGlown, Patient Advocate
Dr. R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Oncology Pharmacist, Professor, and Director of the Phase I Clinical Trials Unit & Clinical Trials Office at Emory Winship Cancer Institute
Leeann Valero, BSN, RN, OCN
Infusion Nurse at University of Illinois Hospital